TY - JOUR
T1 - Neurophysiological findings in long-term survivors of acute lymphoblastic leukaemia in childhood treated with the BFM protocol 81 SR-A/B
AU - Ueberall, M. A.
AU - Skirl, G.
AU - Straßburg, H. M.
AU - Wenzel, D.
AU - Hertzberg, H.
AU - Langer, T.
AU - Meier, W.
AU - Berger-Jones, K.
AU - Huk, W. J.
AU - Korinthenberg, R.
AU - Beck, J. D.
N1 - Funding Information:
Acknowledgements We gratefully acknowledge the engaged contributions of the Late Effects Working Group which consists of paediatricans, neuropaediatricians, paediatric oncologists, psychologists, social care workers and paediatric nurses in eight Children Hospitals in Germany and Austria, who enrolled all study children, who carefully performed all study procedures and who spend much additional time during this study to provide us with detailed information about their patients. We also appreciate the help of Prof. Michaelis and Dr. Kaatsch at the Institute for Medical Statistics and Documentation, University of Mainz, for their contributions in data preparation. This work was supported in part by Deutsche Krebshilfe.
Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1997
Y1 - 1997
N2 - Monitoring of therapy-related late effects after acute lymphoblastic leukaemia (ALL) therapy in child-hood has become an increasingly important field in posttherapeutic patient surveillance. The usefulness of neurophysiological investigations (e.g. EEG, evoked potentials (EP)) as part of these attempts is controversial. The present report focuses on this problem and the question whether and to what extent routinely performed EEG recordings and visual evoked potentials (VEP) were correlated with further measures of CNS integrity. EEGs and VEPs were recorded in 163 asymptomatic long-term survivors of ALL in childhood during a large retrospective multicentre study evaluating CNS late sequelae following antileukaemic therapy. Fifty-two ALL long-term survivors (4.5-10.6 years after end of therapy, median: 8.8 years), who had been treated according to BFM-81 SR-A (n = 30) or SR-B (n = 22) were selected for this analysis focusing on therapy- related CNS late effects. Therapy protocols differed with regard to the mode for CNS prophylaxis: SR-A, cranial irradiation with intrathecal methotrexate: SR-B, intra-thecal and iv methotrexate. Neurophysiological findings were correlated with illness- and treatment-related parameters, as well as with data on the morphological, neurological and psychological status of the CNS. At the time of follow-up neurophysiological measures were abnormal in 28/52 cases (53.8%). Neither illness- nor therapy-specific differences in CNS prophylaxis showed any relationship to EEG VEP outcome any relationship to EEG/VEP outcome in this reduced group of the whole study population. Children with EEG VEP abnormalities showed a significantly higher incidence of structural CNS disturbances compared to those with inconspicuous neurophysiological recordings (60.9% vs 31.8%). However, in this special subject group there was no specific neurophysiological finding for a specific morphological substrate, neurological or psychological deficiency and vice versa. Conclusion routinely performed EEG/VEP investigations are not very helpful measures to predict the presence or degree of behavioural deficiencies, neurological disturbances, or morphological CNS abnormalities. Patients who received cranial irradiation or systemic methotrexate applications showed the same incidence of neurophysiological disturbances without evidence for specific neurotoxic correlates.
AB - Monitoring of therapy-related late effects after acute lymphoblastic leukaemia (ALL) therapy in child-hood has become an increasingly important field in posttherapeutic patient surveillance. The usefulness of neurophysiological investigations (e.g. EEG, evoked potentials (EP)) as part of these attempts is controversial. The present report focuses on this problem and the question whether and to what extent routinely performed EEG recordings and visual evoked potentials (VEP) were correlated with further measures of CNS integrity. EEGs and VEPs were recorded in 163 asymptomatic long-term survivors of ALL in childhood during a large retrospective multicentre study evaluating CNS late sequelae following antileukaemic therapy. Fifty-two ALL long-term survivors (4.5-10.6 years after end of therapy, median: 8.8 years), who had been treated according to BFM-81 SR-A (n = 30) or SR-B (n = 22) were selected for this analysis focusing on therapy- related CNS late effects. Therapy protocols differed with regard to the mode for CNS prophylaxis: SR-A, cranial irradiation with intrathecal methotrexate: SR-B, intra-thecal and iv methotrexate. Neurophysiological findings were correlated with illness- and treatment-related parameters, as well as with data on the morphological, neurological and psychological status of the CNS. At the time of follow-up neurophysiological measures were abnormal in 28/52 cases (53.8%). Neither illness- nor therapy-specific differences in CNS prophylaxis showed any relationship to EEG VEP outcome any relationship to EEG/VEP outcome in this reduced group of the whole study population. Children with EEG VEP abnormalities showed a significantly higher incidence of structural CNS disturbances compared to those with inconspicuous neurophysiological recordings (60.9% vs 31.8%). However, in this special subject group there was no specific neurophysiological finding for a specific morphological substrate, neurological or psychological deficiency and vice versa. Conclusion routinely performed EEG/VEP investigations are not very helpful measures to predict the presence or degree of behavioural deficiencies, neurological disturbances, or morphological CNS abnormalities. Patients who received cranial irradiation or systemic methotrexate applications showed the same incidence of neurophysiological disturbances without evidence for specific neurotoxic correlates.
UR - http://www.scopus.com/inward/record.url?scp=8544253954&partnerID=8YFLogxK
U2 - 10.1007/s004310050700
DO - 10.1007/s004310050700
M3 - Journal articles
C2 - 9296540
AN - SCOPUS:8544253954
SN - 0340-6199
VL - 156
SP - 727
EP - 733
JO - European Journal of Pediatrics
JF - European Journal of Pediatrics
IS - 9
ER -